Results 91 to 100 of about 3,357,233 (168)

Structural Determinants of PARP1 Selectivity from Molecular Dynamics Analysis of PARP1 and PARP2 Complexes. [PDF]

Molecules
Shkil DO, Chesnokova NA, Ivashchenko AA, Petersen EV, Maximov PY.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficient synthesis of imidazo[1,5-a]pyridine sulfonamido derivative as a PARG inhibitor

Tetrahedron
Zhiqun Yu
exaly   +3 more sources

Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat

Brain Research, 2003
Poly(ADP-ribose) is synthesized from nicotinamide adenine dinucleotide (NAD(+)) by poly(ADP-ribose) polymerase (PARP) and degraded by poly(ADP-ribose) glycohydrolase (PARG). Overactivation of the poly(ADP-ribose) pathway increases nicotinamide and decreases cellular NAD(+)/ATP, which leads to cell death.
Jia-He Li
exaly   +4 more sources

Abstract 6972: Discovery of XNW29016, a PARG inhibitor for HRD cancer therapy

Cancer Research
DNA damage repair enzymes are promising targets as genomic instability and DNA repair defects are important characteristics of cancer cells PARylation catalysed by PARP1/2 is a kind of reversible protein modification, which has central functions in ...
Yonghan Hu, Haiyang Wei, Dawei Wan, B. Ma, Jiajing Xu, Shihua Wang, Liang Kong, Zhe Zhang, Yuanbao Li, Zhenwei Wu, Yusong Hou, Wengui Wang, Xiaojun Liu, Meijie Le, Jing-Wen Qiang   +14 more
semanticscholar   +2 more sources

PARG Promotes Esophagus Cancer Cell Metastasis by Activation of the Wnt/β-Catenin Pathway

Biochemical Genetics, 2023
Yehan Zhou, Wang Yalan, Yan Jiaxin
exaly   +2 more sources

Abstract 6093: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors

Cancer Research, 2023
Poly (ADP-ribose) polymerase inhibitors (PARPi) were the first clinically approved drugs designed to exploit synthetic lethality. Despite initial responses, patients harboring homologous recombination (HR) alterations that receive PARPi develop ...
Mona Abed, D. Muñoz, Vidya Seshadri, Stephen Federowicz, A. Rao, Deepthi Bhupathi, M. Liimatta, Rita Ousterhout, Firoz A. Jaipuri, C. Neilan, M. Lackner, Mike White, Z. Mounir   +12 more
semanticscholar   +1 more source

Abstract 6184: Pre-clinical study of SYX3759, a novel PARG inhibitor for the treatment of homologous recombination deficient malignancies

Cancer Research, 2023
Although PARP inhibitors (PARPi) are very successful on the treatment of BRCA-mutant cancer, the tumor spectrum targeted by PARPi is quite narrow. Interestingly, Poly(ADP-ribose) Glycohydrolase (aka PARG), the major dePARylation enzyme, has emerged as ...
Xuzhen Tang, Yaqi Cui, Lan Zhang, Huihui Jin, Zeqiong Xu, Hu He, Chongxun Ge, Song Liu, Xiaochun Yu, Song Shi   +9 more
semanticscholar   +1 more source

DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy

Progress in Biophysics and Molecular Biology, 2021
Poly (ADP-ribosyl)ation has central functions in maintaining genome stability, including facilitating DNA replication and repair. In cancer cells these processes are frequently disrupted, and thus interfering with poly (ADP-ribosyl)ation can exacerbate inherent genome instability and induce selective cytotoxicity. Indeed, inhibitors of poly (ADP-ribose)
Nisha Pillay, Rosie M. Brady, Malini Dey, Robert D. Morgan, Stephen S. Taylor   +4 more
openaire   +4 more sources